Designed for Dynamics
The RHA® Collection is designed to adapt to the dynamic demands of the face, for a look that’s beautiful at rest and flawless in motion.
The RHA® collection of resilient hyaluronic acid (HA) fillers includes RHA® 2, RHA® 3 and RHA® 4. RHA® 2 and RHA® 3 are indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds; and RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds; in adults 22 or older.READ MORE
The RHA® Collection brings you the fourth dimension because it is designed to adapt to facial dynamics.
RHA® has a unique combination of stretch and dynamic strength that makes it resilient enough to accompany, rather than endure, the demands of a constantly moving face.
First Dimension: HA fillers addressed static wrinkles and folds at rest
Second Dimension: HA fillers were engineered to restore volume at rest
Third Dimension: HA fillers addressed static expressions
Fourth Dimension: RHA is designed to adapt to facial dynamics
The RHA® Collection is made with a gentle manufacturing process. Reduced crosslinking allows gel to move dynamically and accompany – rather than endure – the harsh strains of facial dynamics and thus provide durable outcomes.
The RHA® Collection is designed to adapt to the dynamic demands of the face, for a look that’s beautiful at rest and flawless in motion.
TEOXANE took a novel approach and designed a hyaluronic acid filler to more closely resemble natural HA. Preserved Network Technology preserves HA chain length and their intrinsic non-covalent bonds to more closely resemble natural HA.
Proven clinical effectiveness and duration up to 15 months*†
No delayed-onset treatment-related adverse events observed in the US clinical studies*
Clinical effectiveness and safety were demonstrated in 2 pivotal studies, each a 15-month, randomized, double-blinded, within-subject, multicenter, noninferiority, prospective trial. Study 1 (174 subjects): 74 RHA® 2/control treatment group, 74 RHA® 3/control treatment group, and 26 no-treatment group. Study 2 (140 subjects): 120 RHA® 4/control treatment group and 20 no-treatment group.
†Duration based on blinded evaluator assessments at Month 15 in the 2 pivotal studies, the percentages of responders ( ≥ 1 grade improvement on the wrinkle severity rating scale) were 80.9% for RHA 2, 78.7% for RHA 3, and 89.2% for RHA 4.